{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:57:17Z","timestamp":1790834237773,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T00:00:00Z","timestamp":1671235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T00:00:00Z","timestamp":1671235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Respira Therapeutics Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pulmonary arterial hypertension (PAH) is a progressive disease characterized by high mean pulmonary arterial pressure (\u2265\u200920\u2009mmHg) and remodeling of the vascular arteries. Approved therapies improve symptoms and delay clinical worsening in the long term, but they do not relieve acute exertional symptoms. RT234, a drug\/device combination (Respira Therapeutics, Palo Alto, CA, USA) that delivers the phosphodiesterase 5 inhibitor vardenafil to the lungs via inhalation, has been shown to reduce pulmonary vascular resistance in patients with PAH. This study\u00a0aims to evaluate whether RT234 can increase oxygen capacity during cardiopulmonary exercise testing (CPET) in patients with PAH.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This prospective, multi-center, open-label, two-cohort, dose-escalation, phase IIb trial in patients with PAH will evaluate the safety and efficacy of RT234 in improving exercise parameters. The trial began in September 2020 and is expected to be completed by early 2024. Patients eligible for enrollment will have a right heart catheterization\u2013confirmed diagnosis of PAH, a 6-minute walking distance of \u2265\u2009150\u2009m, a minute ventilation\/carbon dioxide production slope of \u2265\u200936, and will be on up to three stable oral and\/or inhaled (not parenteral) PAH-specific\u00a0background therapies. The estimated sample size is 86 patients, who will be divided into two dose cohorts. Cohort 1 will receive 0.5\u2009mg RT234, and cohort 2 will receive 1.0\u2009mg RT234. Each cohort will contain two subgroups based on the number of PAH\u00a0background medications (up to two vs three). The trial will assess patients\u2019 changes from baseline in peak oxygen consumption (VO<jats:sub>2<\/jats:sub>) during CPET 30 minutes after a single dose of 0.5\u2009mg or 1.0\u2009mg RT234, the change in the 6-minute walking distance, and the pharmacokinetics and safety profile of single doses of RT234.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This is the first trial involving an as-needed medication for PAH. The trial will provide insights into the safety and efficacy of as-needed RT234 in treating the acute symptoms of PAH during exercise and will inform the design of further trials.<\/jats:p>\n                <jats:p><jats:italic>Trial registration number:<\/jats:italic> ClinicalTrials.gov identifier NCT04266197.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12931-022-02262-9","type":"journal-article","created":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T01:02:53Z","timestamp":1671238973000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Safety and efficacy of RT234 vardenafil inhalation powder on exercise parameters in pulmonary arterial hypertension: phase II, dose-escalation study design"],"prefix":"10.1186","volume":"23","clinical-trial-number":[{"clinical-trial-number":"nct04266197","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Raymond L.","family":"Benza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandar A.","family":"Aras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Spikes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Grinnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Satler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,17]]},"reference":[{"key":"2262_CR1","doi-asserted-by":"crossref","unstructured":"Gali\u00e8 N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al; ESC Scientific Document Group. 2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37:67\u2013119.","DOI":"10.1093\/eurheartj\/ehv317"},{"key":"2262_CR2","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1183\/09031936.02.00068002","volume":"20","author":"D Chemla","year":"2002","unstructured":"Chemla D, Castelain V, Herve P, Lecarpentier Y, Brimioulle S. Haemodynamic evaluation of pulmonary hypertension. Eur Respir J. 2002;20:1314\u201331.","journal-title":"Eur Respir J"},{"issue":"1 Suppl","key":"2262_CR3","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1016\/j.jacc.2009.04.012","volume":"54","author":"G Simonneau","year":"2009","unstructured":"Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54(1 Suppl):S43\u201354.","journal-title":"J Am Coll Cardiol"},{"key":"2262_CR4","doi-asserted-by":"publisher","first-page":"1801913","DOI":"10.1183\/13993003.01913-2018","volume":"53","author":"G Simonneau","year":"2019","unstructured":"Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53:1801913.","journal-title":"Eur Respir J"},{"key":"2262_CR5","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1161\/CIRCRESAHA.115.301146","volume":"115","author":"YC Lai","year":"2014","unstructured":"Lai YC, Potoka KC, Champion HC, Mora AL, Gladwin MT. Pulmonary arterial hypertension: the clinical syndrome. Circ Res. 2014;115:115\u201330.","journal-title":"Circ Res"},{"key":"2262_CR6","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1097\/JCN.0b013e318275330d","volume":"29","author":"LA Matura","year":"2014","unstructured":"Matura LA, McDonough A, Carroll DL. Health-related quality of life and psychological states in patients with pulmonary arterial hypertension. J Cardiovasc Nurs. 2014;29:178\u201384.","journal-title":"J Cardiovasc Nurs"},{"issue":"1 Suppl","key":"2262_CR7","doi-asserted-by":"publisher","first-page":"S78","DOI":"10.1016\/j.jacc.2009.04.017","volume":"54","author":"RJ Barst","year":"2009","unstructured":"Barst RJ, Gibbs JSR, Ghofrani HA, Hoeper MM, McLaughlin VV, Rubin LJ, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(1 Suppl):S78\u201384.","journal-title":"J Am Coll Cardiol"},{"key":"2262_CR8","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1124\/pr.111.005587","volume":"64","author":"LR Frumkin","year":"2012","unstructured":"Frumkin LR. The pharmacological treatment of pulmonary arterial hypertension. Pharmacol Rev. 2012;64:583\u2013620.","journal-title":"Pharmacol Rev"},{"key":"2262_CR9","unstructured":"The voice of the patient. A series of reports from the U.S. Food and Drug Administration\u2019s (FDA\u2019s) Patient Focused Development initiative: pulmonary arterial hypertension. https:\/\/www.fda.gov\/media\/90479\/download. Accessed 9 Feb 2021."},{"key":"2262_CR10","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1164\/rccm.201101-0093OC","volume":"183","author":"ZC Jing","year":"2011","unstructured":"Jing ZC, Yu ZX, Shen JY, Wu BX, Xu KF, Zhu XY, et al. Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension (EVALUATION) Study Group. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med. 2011;183:1723\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"2262_CR11","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1124\/mol.66.1.144","volume":"66","author":"MA Blount","year":"2004","unstructured":"Blount MA, Beasley A, Zoraghi R, Sekhar KR, Bessay EP, Francis SH, et al. Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation. Mol Pharmacol. 2004;66:144\u201352.","journal-title":"Mol Pharmacol"},{"key":"2262_CR12","unstructured":"Levitra\u00ae. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/021400s011lbl.pdf. Accessed 25 Mar 2022."},{"key":"2262_CR13","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1089\/jamp.2020.1651","volume":"34","author":"MA Eldon","year":"2021","unstructured":"Eldon MA, Parsley EL, Maurer M, Tarara TE, Okikawa J, Weers JG. Safety, tolerability, and pharmacokinetics of RT234 (vardenafil inhalation powder): a first-in-human, ascending single- and multiple-dose study in healthy subjects. J Aerosol Med Pulm Drug Deliv. 2021;34:251\u201361.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"2262_CR14","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0002-8703(03)00119-4","volume":"146","author":"G Wu","year":"2003","unstructured":"Wu G, Sanderson B, Bittner V. The 6-minute walk test: how important is the learning effect? Am Heart J. 2003;146:129\u201333.","journal-title":"Am Heart J"},{"key":"2262_CR15","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1249\/00005768-199409000-00002","volume":"26","author":"DA Mahler","year":"1994","unstructured":"Mahler DA, Horowitz MB. Perception of breathlessness during exercise in patients with respiratory disease. Med Sci Sports Exerc. 1994;26:1078\u201381.","journal-title":"Med Sci Sports Exerc"},{"key":"2262_CR16","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1161\/CIRCULATIONAHA.109.192520","volume":"119","author":"J Myers","year":"2009","unstructured":"Myers J, Arena R, Franklin B, Pina I, Kraus WE, McInnis K, et al. Recommendations for clinical exercise laboratories: a scientific statement from the American Heart Association. Circulation. 2009;119:3144\u201361.","journal-title":"Circulation"},{"key":"2262_CR17","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1249\/00005768-198205000-00012","volume":"14","author":"GA Borg","year":"1982","unstructured":"Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982;14:377\u201381.","journal-title":"Med Sci Sports Exerc"},{"key":"2262_CR18","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s12350-011-9456-y","volume":"18","author":"L Phillips","year":"2011","unstructured":"Phillips L, Wang JW, Pfeffer B, Gianos E, Fisher D, Shaw LJ, et al. Clinical role of the Duke Activity Status Index in the selection of the optimal type of stress myocardial perfusion imaging study in patients with known or suspected ischemic heart disease. J Nucl Cardiol. 2011;18:1015\u201320.","journal-title":"J Nucl Cardiol"},{"key":"2262_CR19","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1249\/00005768-199409000-00003","volume":"26","author":"JN Myers","year":"1994","unstructured":"Myers JN. Perception of chest pain during exercise testing in patients with coronary artery disease. Med Sci Sports Exerc. 1994;26:1082\u20136.","journal-title":"Med Sci Sports Exerc"},{"key":"2262_CR20","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1183\/13993003.00745-2015","volume":"47","author":"L Puente-Maestu","year":"2016","unstructured":"Puente-Maestu L, Palange P, Casaburi R, Laveneziana P, Maltais F, Neder JA, et al. Use of exercise testing in the evaluation of interventional efficacy: an official ERS statement. Eur Respir J. 2016;47:429\u201360.","journal-title":"Eur Respir J"},{"key":"2262_CR21","doi-asserted-by":"publisher","first-page":"e000263","DOI":"10.1136\/bmjresp-2017-000263","volume":"5","author":"J Yorke","year":"2018","unstructured":"Yorke J, Deaton C, Campbell M, McGowen L, Sephton P, Kiely DG, et al. Symptom severity and its effect on health-related quality of life over time in patients with pulmonary hypertension: a multisite longitudinal cohort study. BMJ Open Respir Res. 2018;5:e000263.","journal-title":"BMJ Open Respir Res"},{"issue":"25 Suppl","key":"2262_CR22","doi-asserted-by":"publisher","first-page":"D60","DOI":"10.1016\/j.jacc.2013.10.031","volume":"62","author":"N Gali\u00e8","year":"2013","unstructured":"Gali\u00e8 N, Corris PA, Frost A, Girgis RE, Granton J, Jing ZC, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D60\u201372.","journal-title":"J Am Coll Cardiol"},{"key":"2262_CR23","unstructured":"Keogh A, Dwyer N, Kotlyar E, Kaye D. Acute hemodynamic improvement in chronic pulmonary arterial hypertension on dual therapy following RT234 inhalation. In: Pulmonary Hypertension Association: June 10\u201312, 2022; Atlanta, GA."},{"key":"2262_CR24","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa020204","volume":"347","author":"H Olschewski","year":"2002","unstructured":"Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, et al. Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347:322\u20139.","journal-title":"N Engl J Med"},{"key":"2262_CR25","doi-asserted-by":"publisher","first-page":"e253","DOI":"10.1097\/PCC.0000000000001188","volume":"18","author":"DK Parker","year":"2017","unstructured":"Parker DK, Shen S, Zheng J, Ivy DD, Crotwell DN, Hotz JC, et al. Inhaled treprostinil drug delivery during mechanical ventilation and spontaneous breathing using two different nebulizers. Pediatr Crit Care Med. 2017;18:e253\u201360.","journal-title":"Pediatr Crit Care Med"},{"key":"2262_CR26","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1016\/j.rmed.2015.09.004","volume":"109","author":"NK Ostrom","year":"2015","unstructured":"Ostrom NK, Taveras H, Iverson H, Pearlman DS. Novel albuterol multidose dry powder inhaler in patients with exercise-induced bronchoconstriction: a single-dose, double-blind, randomized, 2-way crossover study. Respir Med. 2015;109:1410\u20135.","journal-title":"Respir Med"},{"key":"2262_CR27","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1161\/01.CIR.67.1.124","volume":"67","author":"A Kimchi","year":"1983","unstructured":"Kimchi A, Lee G, Amsterdam E, Fujii K, Krieg P, Mason DT. Increased exercise tolerance after nitroglycerin oral spray: a new and effective therapeutic modality in angina pectoris. Circulation. 1983;67:124\u20137.","journal-title":"Circulation"},{"key":"2262_CR28","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12890-015-0031-1","volume":"15","author":"R Buys","year":"2015","unstructured":"Buys R, Avila A, Cornelissen VA. Exercise training improves physical fitness in patients with pulmonary arterial hypertension: a systematic review and meta-analysis of controlled trials. BMC Pulm Med. 2015;15:40.","journal-title":"BMC Pulm Med"},{"key":"2262_CR29","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1183\/09059180.00006213","volume":"22","author":"S Gaine","year":"2013","unstructured":"Gaine S, Simonneau G. The need to move from 6-minute walk distance to outcome trials in pulmonary arterial hypertension. Eur Respir Rev. 2013;22:487\u201394.","journal-title":"Eur Respir Rev"},{"key":"2262_CR30","doi-asserted-by":"publisher","first-page":"e694","DOI":"10.1161\/CIR.0000000000000406","volume":"133","author":"M Guazzi","year":"2016","unstructured":"Guazzi M, Arena R, Halle M, Piepoli MF, Myers J, Lavie CJ. 2016 focused update: clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations. Circulation. 2016;133:e694\u2013711.","journal-title":"Circulation"},{"key":"2262_CR31","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/s13643-021-01816-0","volume":"10","author":"SH Sung","year":"2021","unstructured":"Sung SH, Yeh WY, Chiang CE, Huang CJ, Huang WM, Chen CH, et al. The prognostic significance of the alterations of pulmonary hemodynamics in patients with pulmonary arterial hypertension: a meta-regression analysis of randomized controlled trials. Syst Rev. 2021;10:284.","journal-title":"Syst Rev"},{"key":"2262_CR32","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1183\/09059180.00008010","volume":"19","author":"JL Vachi\u00e9ry","year":"2010","unstructured":"Vachi\u00e9ry JL, Simonneau G. Management of severe pulmonary arterial hypertension. Eur Respir Rev. 2010;19:279\u201387.","journal-title":"Eur Respir Rev"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-022-02262-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-022-02262-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-022-02262-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T01:07:11Z","timestamp":1671239231000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-022-02262-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,17]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2262"],"URL":"https:\/\/doi.org\/10.1186\/s12931-022-02262-9","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,17]]},"assertion":[{"value":"19 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial will be conducted in accordance with the Declaration of Helsinki and the Good Clinical Practice Guidelines of the International Conference on Harmonisation, along with all local regulatory requirements. The informed consent document and the protocol have been or will be reviewed and approved by each investigator\u2019s designated Institutional Review Board\/Independent Ethics Committee and by the sponsor. The trial is registered at ClinicalTrials.gov (identifier NCT04266197).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RLB is on the steering committee for Abbott Laboratories, Cereno Scientific, Gossamer Bio, Respira Therapeutics, and United Therapeutics. VF is employed by The Ohio State University, which receives research support from Abbott Laboratories, Acceleron Pharma, Endotronix, Respira Therapeutics, and United Therapeutics. MAA has no interests to declare. LS is the principal investigator for trials sponsored by Acceleron Pharma, Bayer, Gossamer Bio, Insmed, Merck, Respira Therapeutics, and United Therapeutics. DG received grant support from and is on the grant review committee at Bayer and received grant support from Respira Therapeutics. CS is a current employee of Respira Therapeutics.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"355"}}